Dodecafluoropentane emulsion not checked

NuvOx LLC · NanO2TM · NanO2

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 2 trial completes
Trials
2 active
3 in total
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
Tested for
Glioblastoma Multiforme, Mild Respiratory Distress
Main trialPhase 2
“This clinical trial is testing the safety and efficacy of NanO2TM administered via intravenous infusion in combination with standard radiation and chemotherapy. NanO2TM is being developed to increase the amount of oxygen delivered to tumors which is hoped to increase the effectiveness of radiation therapy.”In the company’s words, NCT03862430 on ClinicalTrials.gov
Other names
NanO2TM · dodecafluoropentane · NanO2

Other drugs for Glioblastoma Multiforme

All 94 drugs for Glioblastoma Multiforme

Coming up2

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials3

TrialPhaseCompletesWhat it tests
Phase 2Active, not recruiting 30 Jun 2027 A Study of NanO2™ Combined With Radiation and Temozolomide in Patients With Newly Diagnosed GBM
Phase 1Recruiting Dec 2026 A Dose Escalation Study of NanO2 in Patients With Mild Respiratory Distress
Phase 2/3Unknown 1 Apr 2025 NanO2 for Large Vessel Occlusion Stroke
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026

Follow Dodecafluoropentane emulsion

Following is part of Solo: you see every change to Dodecafluoropentane emulsion the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in